Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations

Oragenics Inc. reported that its audited financial statements for the year ended December 31, 2025 included an unqualified audit opinion with an explanatory paragraph regarding the company’s ability to continue as a going concern. The disclosure was made in accordance with NYSE American requirements and does not reflect any changes to the company’s financial statements or previously filed annual report on Form 10-K, which was filed on March 16, 2026.

The clinical-stage biotechnology company is developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow.

Oragenics’ intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. The company states it is committed to developing innovative therapies that address significant unmet medical needs in neurological care. More information about the company’s programs is available at https://oragenics.com.

The going concern disclosure highlights the financial challenges facing many clinical-stage biotech companies as they advance promising therapies through expensive development phases. While the audit opinion raises questions about the company’s financial sustainability, Oragenics continues to pursue its clinical development timeline for ONP-002, which represents a novel approach to treating traumatic brain injuries through intranasal administration.

The announcement was distributed through InvestorWire, a specialized communications platform that provides wire-grade press release syndication services. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN that delivers various corporate communications solutions. Additional information about the platform is available at https://www.InvestorWire.com.

For investors following the company’s progress, the latest news and updates relating to Oragenics are available in the company’s newsroom at https://ibn.fm/OGEN. The going concern qualification represents a significant disclosure requirement for publicly traded companies when substantial doubt exists about their ability to continue operations, though it does not necessarily indicate imminent business failure but rather flags financial risks that investors should consider alongside the company’s scientific progress.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations.

The post Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations appeared first on citybuzz.